Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Journal of the American Medical Association (JAMA)

• Publication date

  2006-04-05

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.JVS.2006.07.004PMID 16533939
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Intensive lipid lowering with atorvastatin in patients with stable coronary disease.

  2005cited by this paper
• Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease.

  2005cited by this paper
• High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.

  2005cited by this paper
• Regression of Coronary Atherosclerosis by Simvastatin: A Serial Intravascular Ultrasound Study

  2004influential reference
• Effects of the Acyl Coenzyme A:Cholesterol Acyltransferase Inhibitor Avasimibe on Human Atherosclerotic Lesions

  2004cited by this paper
• Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.

  2004cited by this paper
• Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

  2004cited by this paper
• Early Statin Treatment in Patients With Acute Coronary Syndrome: Demonstration of the Beneficial Effect on Atherosclerotic Lesions by Serial Volumetric Intravascular Ultrasound Analysis During Half a Year After Coronary Event: The ESTABLISH Study

  2004cited by this paper
• Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.

  2004cited by this paper
• Intensive versus moderate lipid lowering with statins after acute coronary syndromes.

  2004cited by this paper
• Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial.

  2004cited by this paper
• Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients.

  2003cited by this paper
• Effects of AGI-1067 and Probucol After Percutaneous Coronary Interventions

  2003cited by this paper
• Variability of area measurements obtained with different intravascular ultrasound catheter systems: Impact on clinical trials and a method for accurate calibration.

  2003cited by this paper
• Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial.

  2003cited by this paper
• Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia.

  2002influential reference
• American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents.

  2001cited by this paper
• Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation.

  1995cited by this paper
• Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS).

  1995cited by this paper
• Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS)

  1994cited by this paper
• Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.

  1994cited by this paper
• Coronary Angiographic Changes with Lovastatin Therapy: The Monitored Atherosclerosis Regression Study (MARS)

  1993cited by this paper
• Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.

  1990cited by this paper

• Coronary artery disease in the absence of standard modifiable risk factors (SMuRFs): The impact of sex.

  2026cites this paper
• Low-Density Lipoprotein Cholesterol Longitudinal Trajectories and Clinical Outcomes Following an Acute Coronary Syndrome

  2026cites this paper
• A practical guide to the management of dyslipidaemia

  2026cites this paper
• The efficacy of proprotein convertase subtilisin/kexin 9 inhibitors for coronary atherosclerotic plaque burden and phenotype: A meta-analysis and trial sequential analysis.

  2026cites this paper
• Atherogenic dyslipidaemia and residual cardiovascular risk: Understanding the link to heart disease

  2026cites this paper
• Effects of statins on plaque characteristics of intracranial atherosclerosis assessed by high-resolution magnetic resonance imaging

  2026cites this paper
• Exploratory Characterization of Coronary Thrombi by Integrated Mass Spectrometry and Elemental Imaging in Acute Coronary Syndrome

  2026cites this paper
• Intracoronary Imaging for the Management of Vulnerable Plaques

  2026cites this paper
• Unraveling the temporal sequence of coronary atherosclerosis modification with lipid-lowering therapies through intravascular imaging: a narrative review

  2026cites this paper
• Effects of PCSK9 inhibitors on vascular function, lipid profile, and cardiovascular outcomes in patients with peripheral artery disease: A systematic review and meta-analysis.

  2026cites this paper
• Influence of Intensive Lipid-Lowering With Statin and Ezetimibe Prescription on Computed Tomography-Derived Fractional Flow Reserve in Patients With Stable Chest Pain.

  2026cites this paper
• Impact of TyG index on coronary plaques in patients with coronary artery disease under aggressive lipid-lowering therapy.

  2026cites this paper
• Cardiovascular risk management beyond statins: review of new therapies available in Italy

  2025cites this paper
• Design and rationale of a randomized clinical trial assessing the effect of inclisiran on atherosclerotic plaque in individuals without previous cardiovascular event and without flow- limiting lesions identified in an in-hospital screening - The VICTORION-PLAQUE primary prevention trial.

  2025cites this paper
• Expanding Our Understanding of Plaque Stabilization With PCSK9 Inhibitors.

  2025cites this paper
• From Vision to Illumination: The Promethean Journey of Optical Coherence Tomography in Cardiology

  2025cites this paper
• Changes in non-culprit coronary lesions with PCSK9 inhibitors: the randomised, placebo-controlled FITTER trial.

  2025cites this paper
• Advances in coronary imaging of atherosclerotic plaques.

  2025cites this paper
• Atherosclerotic plaque stabilization and regression.

  2025cites this paper
• Rosuvastatin-based combination treatment with acetylsalicylic acid or ezetimibe in the management of patients at high and very high cardiovascular risk. Expert opinion paper of the Polish Lipid Association 2025

  2025influential citation
• Prediction of Diabetic Neuropathy in Patients with Type 2 Diabetes Mellitus by Using Monocyte to High-Density Lipoprotein Cholesterol Ratio

  2025cites this paper
• Achieved levels of apolipoprotein B and plaque composition after acute coronary syndromes: Insights from HUYGENS.

  2025cites this paper
• Clinical significance of lipoprotein(a) as a residual risk factor for atherosclerotic coronary plaque progression in statin-treated patients with coronary artery disease

  2025cites this paper
• Targeting Vulnerable Plaques in Coronary Artery Disease: Detecting Risk, Preventing Events

  2025cites this paper
• Genetic Risk Score Enables a Vaccine for Early Primary Prevention of CAD

  2025cites this paper
• Inflammation reprogramming and immunomodulation: Next-generation treatments for atherosclerosis

  2025influential citation
• Coronary Plaque Regression: A Review of the Role of Lipid-Lowering Agents

  2025cites this paper
• Advances in the Detection and Management of Vulnerable Coronary Plaques

  2025cites this paper
• Low-Density Lipoprotein Cholesterol Time in Target Range and Clinical Outcomes in the General Population

  2025cites this paper
• Which is the optimal choice in lipid-lowering therapy for reducing major cardiovascular events? a network meta-analysis

  2025cites this paper
• Coronary atherosclerotic plaque modification: the present and the future

  2025cites this paper
• Defining "Vulnerable" in Coronary Artery Disease: Predisposing Factors and Preventive Measures.

  2025cites this paper
• Subclinical Atherosclerosis

  2025cites this paper
• Dynamics of HDL-Cholesterol Following a Post-Myocardial Infarction Cardiac Rehabilitation Program

  2025cites this paper
• Perspectives in the Diagnosis, Clinical Impact, and Management of the Vulnerable Plaque

  2025cites this paper
• Different response of plaque regression following achievement of LDL-C <1.8 mmol/L in obese and non-obese patients with diabetes and coronary artery disease: OPTIMAL sub-analysis.

  2025cites this paper
• Cutting-edge lipid-lowering pharmacological therapies: Improving lipid control beyond statins.

  2025cites this paper
• Initiating Preventive Care for Hyperlipidemia in the Emergency Department: The EMERALD (Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders) Trial.

  2025cites this paper
• Impact of pitavastatin on carotid plaque regression in patients with hypercholesterolemia.

  2025cites this paper
• Achieving More Optimal Lipid Control with Non-Statin Lipid Lowering Therapy

  2025cites this paper
• Evaluation of the effect of statin treatment on intracranial atherosclerotic plaques using magnetic resonance vessel wall imaging: a case series

  2025cites this paper
• Therapeutic PCSK9 targeting: Inside versus outside the hepatocyte?

  2025cites this paper
• Statin-Induced Decade-Long Stabilization of Noncalcified Coronary Plaque Despite a Zero Calcium Score

  2025cites this paper
• Pharmacological regression of atherosclerotic plaque in patients with type 2 diabetes.

  2025cites this paper
• Ophthalmic artery flow reversal and pressure reducing carotid stenosis

  2025cites this paper
• CT-Guided Lipid-Lowering Therapy Leading to Functional Resolution of Ischemia

  2025cites this paper
• The sequence of changes in intravascular imaging findings during lipid-lowering therapy and its implication

  2025cites this paper
• Vulnerable or High-Risk Plaque: A JACC: Cardiovascular Imaging Position Statement.

  2025cites this paper
• Atherosclerotic plaque, cardiovascular risk, and lipid-lowering strategies: a narrative review

  2025cites this paper
• Ferulic acid inhibits ox-LDL-induced ferroptosis and apoptosis in RAW 264.7 cells via the HIF-1 signaling pathway

  2025cites this paper
• Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial.

  2025cites this paper
• A Real-World Retrospective Analysis of Secondary Prevention Patients Treated with Inclisiran over 27 Months

  2025cites this paper
• Lipid-lowering Therapy and Coronary Plaque Regression

  2024cites this paper
• Computed Tomography Angiography Identified High-Risk Coronary Plaques: From Diagnosis to Prognosis and Future Management

  2024cites this paper
• Mineralocorticoid Receptor Antagonism Prevents Aortic Plaque Progression and Reduces Left Ventricular Mass and Fibrosis in Patients With Type 2 Diabetes and Chronic Kidney Disease: The MAGMA Trial

  2024cites this paper
• Statin Use and the Progression of Coronary Artery Calcification in CKD: Findings From the KNOW-CKD Study

  2024cites this paper
• Safety and efficacy of PCSK9 inhibitor (evolocumab) in patients with non-ST segment elevation acute coronary syndrome and non-culprit artery critical lesions: a randomised controlled trial protocol (SPECIAL study)

  2024cites this paper
• Application of high-resolution MRI in evaluating statin efficacy on symptomatic intracranial atherosclerosis

  2024cites this paper
• The LDL cumulative exposure hypothesis: evidence and practical applications

  2024cites this paper
• Review of Recent Literature and Updates in Nonstatin Cholesterol Management.

  2024cites this paper
• Effect of Ayurveda-based Dietary Modification and Panchakarma Therapy on Plaque Stabilization in patients with coronary artery disease – A Prospective Study

  2024cites this paper
• Cardiovascular Imaging for Coronary Artery Disease in Patients with Diabetes Mellitus

  2024cites this paper
• Early, Intensive and Persistent Lipid-Lowering Therapy for Secondary Prevention of Acute Coronary Syndrome

  2024cites this paper
• The clinical relevance of the reversal of coronary atherosclerotic plaque.

  2024cites this paper
• Apolipoprotein B: Bridging the Gap Between Evidence and Clinical Practice

  2024cites this paper
• Emerging Roles and Therapeutic Applications of Arachidonic Acid Pathways in Cardiometabolic Diseases

  2024cites this paper
• Preoperative statins in cardiac surgery: a tale of small study bias or 'the truth, and nothing but the truth'.

  2024cites this paper
• Effects of phytosterol supplementation on lipoprotein subfractions and LDL particle quality

  2024cites this paper
• Role of Lipid-Lowering and Anti-Inflammatory Therapies on Plaque Stabilization

  2024cites this paper
• DEGRADATION ESTIMATION OF ROSUVASTATIN CALCIUM IN PHARMACEUTICAL TABLET FORMULATION

  2024cites this paper
• Association between pre-treatment with statin and its inhibitory effect on the onset of coronary artery disease at the time of coronary computed tomography angiography: a new look at an old medication

  2024cites this paper
• Doenjang Ameliorates Diet-Induced Hyperlipidemia and Hepatic Oxidative Damage by Improving Lipid Metabolism, Oxidative Stress, and Inflammation in ICR Mice

  2024cites this paper
• Drug intervention as an emerging concept for secondary prevention in patients with coronary disease

  2024cites this paper
• Management of Coronary Vulnerable Plaque With Medical Therapy or Local Preventive Percutaneous Coronary Intervention

  2024cites this paper
• Atherosclerotic coronary plaque regression from lipid-lowering therapies: A meta-analysis and meta-regression

  2024influential citation
• Rosuvastatin-Based Lipid-Lowering Therapy for the Control of LDL Cholesterol in Patients at High Vascular Risk

  2024cites this paper
• Enhancing the human health and lifespan: a targeted strategy emphasizing statins

  2024cites this paper
• Trehalose promotes atherosclerosis regression in female mice

  2024cites this paper
• Is there a role for earlier use of combination therapy?

  2024influential citation
• Monoclonal antibodies for dyslipidemia in adults: a focus on vulnerable patients groups

  2024cites this paper
• Effect of combining evolocumab with statin on carotid intraplaque neovascularization in patients with premature coronary artery disease (EPOCH).

  2024cites this paper
• Screening for Subclinical Atherosclerosis and the Prediction of Cardiovascular Events in People with Type 1 Diabetes

  2024cites this paper
• Rosuvastatin effect on atherosclerotic plaque metabolism: A subclinical atherosclerosis imaging study with 18F-NaF PET-CT.

  2024cites this paper
• Evaluating different low‐density lipoprotein cholesterol thresholds to initiate statin for prevention of cardiovascular diseases in patients with type 2 diabetes mellitus: A target trial emulation study

  2024cites this paper
• Role of intravascular ultrasound and optical coherence tomography in intracoronary imaging for coronary artery disease: a systematic review.

  2024cites this paper
• Retrospective Evaluation of LDL-C Levels Following First Treatment With Inclisiran as Part of Secondary Prevention ASCVD Risk Reduction in a Real-World Primary Care Setting

  2024cites this paper
• Managing hypercholesterolaemia

  2024influential citation
• Cholesterol-Lowering Strategies for Cardiovascular Disease Prevention: The Importance of Intensive Treatment and the Simplification of Medical Therapy

  2024cites this paper
• Eliminate LDL cholesterol after heart attack … but only for a while

  2024cites this paper
• Deferred revascularization in diabetic patient according to combined invasive functional and intravascular imaging data: A case report

  2024cites this paper
• How Will Our Practice Change After the CLEAR Outcomes Trial?

  2024cites this paper
• Effect of moderate-intensity statin on carotid intraplaque neovascularization of coronary artery disease: a retrospective cohort study

  2024cites this paper
• The role of ABCC10/MRP7 in anti-cancer drug resistance and beyond.

  2024cites this paper
• The vulnerable or high-risk plaque and coronary thrombotic events

  2024cites this paper
• Invasive coronary imaging of inflammation to further characterize high-risk lesions: what options do we have?

  2024cites this paper
• Atherosclerotic plaque stabilization and regression: a review of clinical evidence

  2024cites this paper
• Impact of eicosapentaenoic acid on cardiovascular outcomes after acute coronary syndrome: a systematic review and meta-analysis of randomized clinical trials

  2024cites this paper
• The Evaluation of Lipid-Lowering Treatment in Patients with Acute Coronary Syndrome in a Hungarian Invasive Centre in 2015, 2017, and during the COVID-19 Pandemic—The Comparison of the Achieved LDL-Cholesterol Values Calculated with Friedewald and Martin–Hopkins Methods

  2024cites this paper
• Top 10 Tips for Using Statins in Clinical Practice.

  2024cites this paper
• Statin therapy in primary and secondary cardiovascular disease prevention

  2024cites this paper